[go: up one dir, main page]

US20120123105A1 - Gene Signature for Diagnosis and Prognosis of Breast Cancer and Ovarian Cancer - Google Patents

Gene Signature for Diagnosis and Prognosis of Breast Cancer and Ovarian Cancer Download PDF

Info

Publication number
US20120123105A1
US20120123105A1 US13/340,003 US201113340003A US2012123105A1 US 20120123105 A1 US20120123105 A1 US 20120123105A1 US 201113340003 A US201113340003 A US 201113340003A US 2012123105 A1 US2012123105 A1 US 2012123105A1
Authority
US
United States
Prior art keywords
seq
breast cancer
gene
risk
gene signature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/340,003
Inventor
Nancy Lan Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/340,003 priority Critical patent/US20120123105A1/en
Publication of US20120123105A1 publication Critical patent/US20120123105A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • FIG. 1 is a Time dependent ROC analyses of the 28-gene signature in disease-free survival prediction in three breast cancer patient cohorts.
  • FIG. 2 is a Time dependent ROC analyses of the 28-gene signature in disease-free survival prediction in three breast cancer patient cohorts.
  • FIG. 2 is a AUC in year 1 to year 11 during follow-up after surgery in the patient cohort from Sotiriou et al. (8).
  • FIG. 3 is a Time dependent ROC analyses of the 28-gene signature in disease-free survival prediction in three breast cancer patient cohorts.
  • AUC 0.843 with 25 overlapping genes on data from van't Veer et al.(27)
  • AUC 0.764 with 8 overlapping genes on data from Sorlie et al. (10).
  • FIG. 4 is a Time dependent ROC analyses of the 28-gene signature in disease-free survival prediction in three breast cancer patient cohorts.
  • FIG. 4 is a AUC in year 1 to year 13 during follow-up after surgery on two independent patient cohorts (10; 28).
  • FIG. 5 is a Time-dependent ROC analyses of the 28-gene signature in overall survival prediction in there breast cancer patient cohorts.
  • FIG. 6 is a Time-dependent ROC analyses of the 28-gene signature in overall survival prediction in there breast cancer patient cohorts.
  • FIG. 6 is the area under the ROC curve (AUC) of overall survival prediction during the follow-up after surgery.
  • FIG. 7 is a Time-dependent ROC analyses of 15 genes within the 28-gene signature in relapse-free survival prediction in three breast cancer patient cohorts.
  • FIG. 8 is a Time-dependent ROC analyses of 15 genes within the 28-gene signature in relapse-free survival prediction in three breast cancer patient cohorts.
  • FIG. 9 is a Time-dependent ROC analyses of 15 genes within the 28-gene signature in relapse-free survival prediction in three breast cancer patient cohorts.
  • FIG. 10 is a Time-dependent ROC analyses of 24 genes within the 28-gene signature in relapse-free survival prediction in one ovarian cancer patient cohort from Marsh et al. (29)
  • a first embodiment in this application can be an expression profile-defined prognostic model able to predict the recurrence and metastases of breast cancer and ovarian cancer by using unique gene expression patterns in tumors. Additionally, the expression profile-defined prognostic model may be used to predict the relapse-free interval and metastases-free interval.
  • the expression based profile-defined prognostic model has been developed and is a highly accurate predictor of disease-free survival as well as overall survival in individual breast cancer patients.
  • the expression based profile-defined prognostic model can be a gene signature such as a 15-gene signature, a 23-gene signature, or a 28-gene signature comprised of a combination of the following genes (Table 1).
  • a Linear Discriminant Analysis function classified 5-year relapse status for patients provided an accuracy of 0.92, a sensitivity of 0.90, and a specificity of 0.95.
  • a Cox proportional hazards model was built on the 28-gene signature and the risk score was used to construct the time-dependent receiver operating curve (ROC).
  • the area under the ROC curve (AUC) during year five was 0.983 ( FIG. 1 ), and remained 0.92 between years 8 and 11 during the follow up ( FIG. 2 ).
  • 15 genes (Table 5) predict disease-free survival with an accuracy ranging from 0.79 to 0.92 in three patient cohorts from Sotiriou et al. (8), van't Veer et al. (12), and Sorlie et al. (10) ( FIGS. 7 , 8 , and 9 ). These 15 genes can be used as a 15-gene signature prognostic model for breast cancer.
  • the 8 unique genes from Table 4 may be added to form a 23-gene signature prognostic model for breast cancer.
  • the remaining 5 unique genes from Table 1 form a 28-gene signature prognostic model for both breast and ovarian cancer. Together, genes in Tables 4 and 5 can predict both breast cancer relapse and metastases.
  • risk scores can be generated by using a Cox model of the 28-gene signature, independent of clinical-pathological parameters although any standard risk evaluation could be used. In this appication large value of the risk scores indicates a high risk of relapse/metastases, while a small value indicates a lower risk of breast cancer relapse.
  • the 28-gene signature obtained from the training set (8) was fitted into a Cox regression model as covariates. To avoid overfitting, the data set are randomly partitioned into two subsets—one was used to define risk groups by fitting the model and obtaining the risk score cutoffs; the other subset was used to validate the cutoffs for defining the risk groups.
  • the distribution of the risk scores can be categorized into groups of two or more. If two groups, patients could be labeled as high risk at the 65 th percentile or above and low risk at 64 th percentile and below. Alternatively, the patients could be categorized into high, low, or intermediate risk group is 39%, 26%, and 35%, respectively in the training set.
  • the cutoffs defined in the training subset can be used to separate the patients in the test subset into high, low and intermediate risk groups.
  • a further embodiment is the ability to evaluate clincopathogic variables for cancer patients.
  • Clincopathogic variable includes, but is not limited to, average metastases-free days, ER and PR status, age, tumor size, and tumor grade.
  • Table 6 displays the clinical characteristics of each risk group, including average relapse-free days, ER status, Her2/neu overexpression, nodal status, age, tumor size, and treatment received on the data from Sotiriou et al.(8).
  • Risk scores were generated for patients in Cox modeling using the gene expression profiles, without including clinicopathologic parameters. The 39 th and 65 th percentile of the risk scores were used to partition patients into high, intermediate, and low risk groups. Same analysis is applied to the two validation sets.
  • Table 7 summarizes the clinical characteristics of each risk group, including average metastases-free days, ER and PR status, age, tumor size, and tumor grade on the data from van't Veer et al. (13).
  • Table 8 summarizes the clinical characteristics of each risk group, including average relapse-free days, ER status, age, and tumor grade on the data from Sorlie et al.(10).
  • Clinical variables such as nodal status, tumor size, tumor grade, ER status and HER2/neu overexpression in breast cancer patients affect the disease outcomes.
  • the clinical characteristics of each risk group in the studied cohorts are analyzed including average disease-free survival days, ER and PR status, HER2/neu overexpression, nodal status, age, tumor size, grade, and treatment received.
  • the 28-gene signature is strongly associated with the clincopathogic variables, including tumor size, tumor grade, ER and PR status, and HER2/neu overexpression (P ⁇ 0.05; Table 9).
  • the 28-gene signature also predicts tumor recurrence in ovarian cancer with an accuracy of 0.89 ( FIG. 10 ).
  • Table 10 listed the genes that are predictive of ovarian cancer relapse.
  • target polynucleotide molecules are extracted from a sample taken from an individual afflicted with breast cancer or ovarian cancer.
  • the sample may be collected in any clinically acceptable manner, but must be collected such that marker-derived polynucleotides (i.e., RNA) are preserved.
  • marker-derived polynucleotides i.e., RNA
  • mRNA or nucleic acids derived there from i.e., cDNA or amplified DNA
  • a detection mechanism can be any standard comparison mechanism such as a microarray or an assay of reverse transcription polymerase chain reaction (RT-PCR) comprising some or all of the markers or marker sets or subsets described above.
  • RT-PCR reverse transcription polymerase chain reaction
  • a sample may comprise any clinically relevant tissue sample, such as a tumor biopsy or fine needle aspiration, or a sample of bodily fluid, such as blood, plasma, serum, lymph, ascetic fluid, cystic fluid, urine, or nipple exudate.
  • the sample may be taken from a human, or from non-human animals such as horses, mice, ruminants, swine or sheep.
  • Patients' gene expression levels may be quantified by any means known in the art based on the marker sets defined above. Patients may be classified based on the quantitative expression profiles using any means known in the art. For example, the risk scores of a patient cohort may be generated using a Cox proportional hazard model. Patients with a risk score greater than the median is defined as high risk, whereas patients with a risk score less than the median is classified as low risk. Alternatively, a patient may be classified as high risk if this patient's gene expression profile is correlated with the high risk signature, or classified as low risk if this patient's gene expression profile is correlated with the low risk signature.
  • a patient's prognostic categorization can also be determined by using a statistical model or a machine learning algorithm, which computes the probability of recurrence based on this patient's gene expression profiles. Cutoffs can be defined for patient stratification based on specific clinical setting. In addition, patients may be defined into three risk groups in the prognostic categorization based on the marker sets defined above.
  • RNA may be isolated from eukaryotic cells by procedures that involve cell lysis and denaturation of the proteins contained therein.
  • Cells of interest include wide-type cells (i.e., no mutation), drug-treated wild-type cells, tumor- or tumor-derived cells, modified cells, normal or tumor cell lines cells, and drug-treated modified cells.
  • Total RNA may also be extracted from samples using commercially available kits such as the RNeasy mini kit according the manufacturer's protocol (Qiagen, USA).
  • RNA may be purified by means such as magnetic separation using Dynabeads (Dynal) or the Invitrogen FastTrack 2.0 kit (10).
  • RNA transfer RNA
  • rRNA ribosomal RNA
  • Total RNA may also be linearly amplified using the original or modified Eberwine method (18) and be used as a reference for cDNA analysis (8).
  • the sample of RNA can comprise a plurality of different mRNA molecules, each different mRNA molecular having a different nucleotide sequence.
  • the RNA sample has not been functionally annotated.
  • the present invention provides a set of biomarkers for the identification of conditions of indications associated with breast cancer.
  • the markers sets were identified by determining which of ⁇ 25,000 human genes had expression patterns that correlated with the conditions or indications.
  • the expression of all markers in a sample X is compared to the expression of all markers in the 28-gene signature or subsets as described above derived from tumor samples.
  • the comparison may be accomplished by any means known in the art.
  • the expression level may be determined by isolating and determining the level (i.e., the abundance) of nucleic acid transcribed from each marker gene.
  • the level of specific proteins translated from mRNA transcribed from a marker gene may be determined.
  • expression levels of various markers may be measured by separation of target nucleotide molecules (e.g., RNA or cDNA) derived from the markers in agarose or polyacrylamide gels, followed by hybridization with marker-specific oligonucleotide probes.
  • target nucleotide molecules e.g., RNA or cDNA
  • the comparison may be accomplished by the labeling of target polynucleotide molecules followed by separation on a sequence gel.
  • the comparison may also be accomplished by measuring the gene expression level using real-time reverse transcription polymerase chain reaction with marker-specific primers/probes.
  • Patients may be classified based on the quantitative expression profiles using any means known in the art. For example, the risk scores of a patient cohort may be generated using a Cox proportional hazard model. Patients with a risk score greater than the median is defined as high risk, whereas patients with a risk score less than the median is classified as low risk.
  • a patient may be classified as high risk if this patient's gene expression profile is correlated with the high risk signature, or classified as low risk if this patient's gene expression profile is correlated with the low risk signature.
  • a patient's prognostic categorization can also be determined by using a statistical model or a machine learning algorithm, which computes the probability of recurrence based on this patient's gene expression profiles. Cutoffs can be defined for patient stratification based on specific clinical setting. In addition, patients may be defined into three risk groups in the prognostic categorization based on the marker sets defined above.
  • a marker is selected based on its predictive power of breast cancer recurrence, including local recurrence and distant metastasis.
  • a combination of Random Forests (19) and Linear Discriminant Analysis (LDA) is used to identify gene signatures for predicting breast cancer recurrence/metastases. Random forests of software R is first used to identify a small subset of genes from the original microarray data. Linear Discriminant Analysis of software SAS is used to further refine the gene signature.
  • Random forests are a generalization of the standard tree algorithms (20).
  • the basic step of random forests is to form diverse tree classifiers from a single training set. Each tree is built upon a bootstrap sample from the training set.
  • the variables used for splitting the tree nodes are a random subset of the whole variables set.
  • the classification decision of a new case is obtained by majority voting (unless the cutoff value is user defined) over all trees.
  • OOB out-of-bag
  • a very important function of random forests is variable importance evaluation. The importance of a variable is defined in terms of its contribution to classification accuracy.
  • the varSelRF package of software R (21) was used according to the following steps:
  • the “0-Standard Error (0-SE) rule” is used, which identifies the gene subset with the smallest OOB error rate.
  • the “0-SE rule” usually selects more genes than the “1-SE rule” does. Since further gene filtering would be performed by using Linear Discriminant Analysis, the gene subsets are selected with the lowest prediction error using random forests.
  • Discriminant analysis is used to determine which variables discriminate two or more naturally occurring groups in prognosis. Given a number of variables as the data representation, each class is modeled as multivariate normal distribution with a covariance matrix and a mean vector. Instances are classified to the label of the nearest mean vector based on Mahalanobis distance. The decision surfaces between classes become linear if the classes have a common covariance matrix.
  • a parametric method can be used to develop a discriminant function. Such function is determined by a measure of generalized square distance which is based on the pooled covariance matrix as well as the prior probabilities of group membership.
  • the generalized squared distance D i 2 (x) from input x to class i is:
  • m is the p-dimensional mean vector for group I;
  • V is the pooled covariance matrix and g(i) depends on the prior probability of class i.
  • x is classified into class I, if D i 2 (x) is the smallest among all the distance measures.
  • LDA Linear Discriminant Analysis
  • time-dependent receiver operating characteristic (ROC) analysis for censored data (23; 24) was performed with software R.
  • ROC receiver operating characteristic
  • time-dependent ROC analysis extends the concepts of sensitivity, specificity, and ROC curves for time-dependent binary disease variables in censored data.
  • sensitivity and specificity are defined as a function of time t:
  • a ROC(t) is a function of t at different cutoffs c.
  • a time-dependent ROC curve is a plot of sensitivity(c, t) vs. 1 ⁇ specificity(c, t).
  • the area under the ROC curve (AUC) can be used as an accuracy measure of the ROC curve. A higher prediction accuracy is evidenced by a larger AUC(t) (23; 24).
  • the prediction of patient outcome may be accomplished with any means known in the art. For example, to estimate a patient's recurrent and metastatic potential, risk scores are generated by fitting the identified gene predictors in a Cox proportional hazard model as covariates. A higher risk score represents a higher probability of tumor recurrence.
  • the distribution of the risk scores can be used to classify the patients into three groups: high-risk, low-risk, and intermediate-risk. Alternatively, patients may be stratified into two groups: high- or low-risk. Kaplan-Meier analysis may be used to assess the disease-free survival probability of three risk groups in the studied patient cohorts (8; 10; 25). Similarly, a Cox proportional hazard model may be developed to estimate a patient's overall survival probability.
  • LDA Linear Discriminant Analysis
  • the expression levels of the markers can be measured with any means known in the art such as cDNA microarrays (8; 10; 26), various generations of Affymetrix gene chips (Affymetrix, Santa Clara, Calif.), and real-time reverse transcription polymerase chain reactions.
  • the present invention further provides for kits comprising the marker sets above.
  • the analytical methods described above can be implemented by use of following computer systems.
  • a computer system can be an Intel 8086-, 80386-, 80486-, or Pentium-based process with preferably 64 MB or more of main memory.
  • the computer system can be linked to an external component, including mass storage. This mass storage can be one or more hard disks, preferably of 1 GB or more storage capacity. Other external components include regular accessories for a computer such as a monitor, a mouse, or a printer.
  • the software program described in above sections can be implemented with software packages R and SAS.
  • the software to be included in the kit comprises the data analysis methods for this invention as disclosed herein.
  • the software algorithms may include mathematical procedures for biomarker discovery, including the computation of the Mahalanobis distance between clinical categories (i.e., relapse status) and marker expression.
  • the software may also include mathematical procedures for computing the regression coefficients between the marker expression and patient survival.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Software Systems (AREA)
  • Public Health (AREA)
  • Evolutionary Computation (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A first embodiment is a breast cancer prognosticator comprising a detection mechanism consisting a 15-gene signature. In addition there are embodiments comprised of 23-gene signatures and 28-gene signatures. The 28-gene signature may also be used for the prognosis of ovarian cancer. Another embodiment is a method to determine relapse free potential in breast cancer patients comprising collecting a sample from an individual, removing marker-derived polynucleotide from said sample, using a detection mechanism to search for positive matches of said polynucleotides and a 24-gene signature, and developing a quantitative expression profile.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a Continuation of U.S. patent application Ser. No. 12/661,286 which was filed on Mar. 15, 2010 which was a Divisional of U.S. patent application Ser. No. 12/077,992 filed on Mar. 24, 2008.
    • REFERENCE TO SEQUENCE LISTING, A TABLE, OR A COMPUTER PROGRAM LISTING COMPACT DISC APPENDIX
  • This application contains a Sequence Listing submitted on compact disk containing file name 387.Seq. The sequence listing on the compact disc is incorporated by reference herein in its entirety.
    • BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
  • The following figures are not drawn to scale and are for illustrative purposes only.
  • FIG. 1 is a Time dependent ROC analyses of the 28-gene signature in disease-free survival prediction in three breast cancer patient cohorts. FIG. 1 is a Time dependent ROC (t=5 years) curve of the 28-gene signature on the training set from Sotiriou et al. (8) The area under the ROC curve (AUC)=0.983.
  • FIG. 2 is a Time dependent ROC analyses of the 28-gene signature in disease-free survival prediction in three breast cancer patient cohorts. FIG. 2 is a AUC in year 1 to year 11 during follow-up after surgery in the patient cohort from Sotiriou et al. (8).
  • FIG. 3 is a Time dependent ROC analyses of the 28-gene signature in disease-free survival prediction in three breast cancer patient cohorts. FIG. 3 is a Time-dependent ROC (t=5 years) curves of the 28-gene signature on two validation sets. AUC=0.843 with 25 overlapping genes on data from van't Veer et al.(27) AUC=0.764 with 8 overlapping genes on data from Sorlie et al. (10).
  • FIG. 4 is a Time dependent ROC analyses of the 28-gene signature in disease-free survival prediction in three breast cancer patient cohorts. FIG. 4 is a AUC in year 1 to year 13 during follow-up after surgery on two independent patient cohorts (10; 28).
  • FIG. 5 is a Time-dependent ROC analyses of the 28-gene signature in overall survival prediction in there breast cancer patient cohorts. FIG. 5 is a Time-dependent ROC curves at time=5 years. AUC=0.927 on data from Sotiriou et al. (8) AUC=0.808 on data from Sorlie et al. (10)
  • FIG. 6 is a Time-dependent ROC analyses of the 28-gene signature in overall survival prediction in there breast cancer patient cohorts. FIG. 6 is the area under the ROC curve (AUC) of overall survival prediction during the follow-up after surgery.
  • FIG. 7 is a Time-dependent ROC analyses of 15 genes within the 28-gene signature in relapse-free survival prediction in three breast cancer patient cohorts. FIG. 7 are Time-dependent ROC curves at time=5 years. AUC=0.92 on data from Sotiriou et al. (8)
  • FIG. 8 is a Time-dependent ROC analyses of 15 genes within the 28-gene signature in relapse-free survival prediction in three breast cancer patient cohorts. FIG. 8 are Time-dependent ROC curves at time=5 years. AUC=0.87 on data from Sorlie et al. (10)
  • FIG. 9 is a Time-dependent ROC analyses of 15 genes within the 28-gene signature in relapse-free survival prediction in three breast cancer patient cohorts. FIG. 9 are Time-dependent ROC curves at time=5 years. AUC=0.79 on data from van't Veer et al. (26).
  • FIG. 10 is a Time-dependent ROC analyses of 24 genes within the 28-gene signature in relapse-free survival prediction in one ovarian cancer patient cohort from Bild et al. (29)
    •  DETAILED DESCRIPTION OF THE INVENTION
  • A first embodiment in this application can be an expression profile-defined prognostic model able to predict the recurrence and metastases of breast cancer and ovarian cancer by using unique gene expression patterns in tumors. Additionally, the expression profile-defined prognostic model may be used to predict the relapse-free interval and metastases-free interval. The expression based profile-defined prognostic model has been developed and is a highly accurate predictor of disease-free survival as well as overall survival in individual breast cancer patients. The expression based profile-defined prognostic model can be a gene signature such as a 15-gene signature, a 23-gene signature, or a 28-gene signature comprised of a combination of the following genes (Table 1).
  • TABLE 1
    28 genes that quantifies disease-free survival
    and overall survival of breast cancer
    UniGene
    Gene Clone_IMAGE Cluster ID Sequence ID Seq. ID No
    FAM134C 198917 Hs.463079 NM_178126   Seq. ID No 30
    TOMM70A 198312 Hs.227253 NM_014820   Seq. ID No 7 
    MCF2 268412 Hs.387262 NM_001099855 Seq. ID No 8 
    NM_005369   Seq. ID No 9 
    RAD52 1377154 Hs.552577 NM_134424   Seq. ID No 10
    Pseudogene
    MCM2 239799 Hs.477481 NM_004526   Seq. ID No 11
    C18B11 131988 Hs.173311 NM_152260   Seq. ID No 12
    SEC13L 757210 Hs.301048 NM_031216   Seq. ID No 13
    NM_001013437 Seq. ID No 14
    SLC25A5 291660 Hs.522767 NM_001152   Seq. ID No 15
    PLSCR1 268736 Hs.130759 NM_021105   Seq. ID No 16
    TXNRD1 789376 Hs.434367 NM_003330   Seq. ID No 17
    NM_001093771 Seq. ID No 18
    NM_182742   Seq. ID No 19
    NM_182729   Seq. ID No 20
    NM_182743   Seq. ID No 21
    RAD50 261828 Hs.242635 NM_005732   Seq. ID No 22
    NM_133482   Seq. ID No 23
    — 46196 BX100884 Seq. ID No 4 
    H09243 Seq. ID No 5 
    H09242 Seq. ID No 6 
    INPPL1 703964 Hs.523875 NM_001567   Seq. ID No 24
    — 501651 Hs.439445 AK025546 Seq. ID No 3 
    PBX2 80549 Hs.509545 NM_002586   Seq. ID No 25
    SSBP1 125183 Hs.490394 NM_003143   Seq. ID No 26
    — 34396 Hs.448229 BE870371 Seq. ID No 1 
    PDGFRA 376499 Hs.74615  NM_006206   Seq. ID No 27
    ACOT4 488202 Hs.49433  NM_152331   Seq. ID No 28
    DDOST 50666 Hs.523145 NM_005216   Seq. ID No 29
    IGHA1 182930 Hs.497723 AK128652 Seq. ID No 30
    S100P 135221 Hs.2962  NM_005980   Seq. ID No 31
    FAT 591266 Hs.481371 NM_005245   Seq. ID No 32
    FGF2 324383 Hs.284244 NM_002006   Seq. ID No 33
    INSM1 22895 Hs.89584  NM_002196   Seq. ID No 34
    IRF5 260035 Hs.521181 NM_001098629 Seq. ID No 35
    NM_002200   Seq. ID No 36
    NM_001098627 Seq. ID No 37
    NM_001098630 Seq. ID No 38
    NM_001098628 Seq. ID No 39
    NM_032643   Seq. ID No 40
    NM_001098631 Seq. ID No 41
    SMARCD2 741067 Hs.250581 NM_001098426 Seq. ID No 42
    NM_003077   Seq. ID No 43
    MAP2K2 769579 Hs.465627 NM_030662   Seq. ID No 44
  • There is no overlap between the disclosed gene signature and previously reported gene signatures. Of the 28 genes in Table 1, 17 are related to tumorigenesis (Table 2) and 9 genes are linked to breast cancer pathogenesis (Table 3). Furthermore, among the nine breast cancer-related genes, five genes are established breast cancer biomarkers ((MCM2, Rad50, PDGFRA, S100P, and FGF2) (Table 3)).
  • TABLE 2
    Genes that are related to tumorigenesis
    Gene Gene Name Function
    MCF2 Mcf.2 cell line derived Guanine nucleotide
    transforming sequence exchange factor
    MCM2 Mcm2 minichromosome DNA replication
    maintenance deficient 2,
    mitotin
    SEC13L Seh1-like mRNA export, nuclear
    pore distribution
    and cell division
    PLSCR1 Phospholipid Lipid transfer
    scramblase 1 signaling
    RAD50 RAD50 homolog DNA repair
    INPPL1 Inositol polyphosphate Lipid metabolism
    phosphatase-like 1
    TXNRD1 Thioredoxin reductase 1 Antioxidant and
    redox regulator
    PBX2 Pre-b-cell leukemia Transcriptional repressor
    transcription factor
    2 and tumor suppressor
    SSBP1 Single-stranded dna DNA binding protein
    binding protein
    1
    PDGFRA Platelet-derived growth Growth factor receptor
    factor receptor
    S100P S100 calcium binding Cell differentiation
    protein p
    FAT Fat tumor suppressor Cell signaling
    homolog
    1 suppressor
    FGF2 Fibroblast growth factor 2 Signaling tranduction
    INSM1 Insulinoma-associated 1 Transcriptional repressor
    IRF5 Interferon regulatory factor 5 Tumor suppressor gene
    SMARCD2 Swi/snf related, matrix chromatin remodelling
    associated, actin dependent
    regulator of chromatin,
    subfamily d, member 2
    MAP2K2 Mitogen-activated Signaling transduction
    protein kinase kinase 2
  • TABLE 3
    Genes that are linked to breast cancer pathogenesis
    Breast Cancer
    Gene Gene Name Function Involvement
    MCF2 Mcf.2 cell line Guanine (+)
    derived transforming nucleotide
    sequence exchange factor
    MCM2 Mcm2 DNA (+)
    minichromosome replication biomarker (1)
    maintenance
    deficient 2, mitotin
    RAD50 DNA repair (+)
    biomarker (2)
    TXNRD1 Thioredoxin Antioxidant (+)
    reductase 1 and redox
    regulator
    PDGFRA Platelet-derived Growth (+)
    growth factor factor biomarker (3; 4)
    receptor receptor
    S100P S100 calcium Cell (+)
    binding protein p differentiation biomarker (5; 6)
    FGF2 Fibroblast growth Signaling (+)
    factor 2 tranduction biomarker (7)
    SMARCD2 Swi/snf related, chromatin (+)
    matrix associated, remodelling
    actin dependent
    regulator of
    chromatin, subfamily
    d, member 2
    MAP2K2 Mitogen-activated Signaling (+)
    protein kinase transduction
    kinase
    2
  • Based upon the expression profiles of these 28 genes in the data from Sotiriou et al. (8), a Linear Discriminant Analysis function classified 5-year relapse status for patients provided an accuracy of 0.92, a sensitivity of 0.90, and a specificity of 0.95. To evaluate relapse-free survival prediction, a Cox proportional hazards model was built on the 28-gene signature and the risk score was used to construct the time-dependent receiver operating curve (ROC). The area under the ROC curve (AUC) during year five was 0.983 (FIG. 1), and remained 0.92 between years 8 and 11 during the follow up (FIG. 2).
  • To evaluate the prognostic power of the identified gene signature, two independent validation sets were used (9; 10). Using the signature genes, time-dependent ROC analyses were performed to evaluate relapse/metastases prediction on two independent patient cohorts (FIGS. 3 and 4). The area under the ROC (5-year) curve on the data from van't Veer et al. (11) was 0.843 with 25 signature genes in predicting metastatic potential. The AUC (5-year) was 0.764 on the data from Sorlie et al. (10) with eight overlapped genes in the relapse-free survival prediction (FIG. 3).
  • Time dependent ROC analysis showed that the 28-gene signature was also predictive of overall survival (P<0.001; FIGS. 5 and 6). In the prediction of overall survival , the AUC (5-year) was 0.927 on data from Sotiriou et al. (Sotiriou C. et al., Breast Cancer classification and prognosis based on gene expression profiles from a population-based study, Proc. Natl. Acad. Sci., USA 2003; 100:10393-8) and 0.808 on data from Sorlie et al. (Sorlie T. et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc. Natl. Acad. Sci., USA 2001; 98:10869-74).
  • Among the 28-gene signature, 11 genes had significant association with relapse-free survival in Cox modeling (Table 4).
  • TABLE 4
    Genes that are significantly associated with breast
    cancer relapse
    GENE P-value Seq. ID No.
    FGF2 0.0039 Seq. ID No 33  
    SLC25A5 0.0051 Seq. ID No 15  
    C18B11 0.0062 Seq. ID No 12  
    SMARCD2 0.0087 Seq. ID No 42-43
    TOMM70A 0.0250 Seq. ID No 7  
    PBX2 0.0330 Seq. ID No 25  
    SEC13L 0.0350 Seq. ID No 13-14
    Clone ID: 501651 0.0350 Seq. ID No 3  
    IRF5 0.0350 Seq. ID No 35-41
    DDOST 0.0470 Seq. ID No 29  
    Clone ID: 182930 0.0520 Seq. ID No 30  
  • Among the 28-gene set, 15 genes (Table 5) predict disease-free survival with an accuracy ranging from 0.79 to 0.92 in three patient cohorts from Sotiriou et al. (8), van't Veer et al. (12), and Sorlie et al. (10) (FIGS. 7, 8, and 9). These 15 genes can be used as a 15-gene signature prognostic model for breast cancer. In addition, the 8 unique genes from Table 4 may be added to form a 23-gene signature prognostic model for breast cancer. The remaining 5 unique genes from Table 1 form a 28-gene signature prognostic model for both breast and ovarian cancer. Together, genes in Tables 4 and 5 can predict both breast cancer relapse and metastases.
  • TABLE 5
    Genes that predicts breast cancer relapse
    GENE CLONE ID Seq. ID No
    MAP2K2 769579 Seq. ID No 44  
    SMARCD2 741067 Seq. ID No 42-43
    S100P 2060823 Seq. ID No 31  
    FAT 591266 Seq. ID No 32  
    DDOST 50666 Seq. ID No 29  
    SSBP1 125183 Seq. ID No 26  
    PDGFRA 1643186 Seq. ID No 27  
    INPPL1 703964 Seq. ID No 24  
    RAD50 261828 Seq. ID No 22-23
    PLSCR1 268736 Seq. ID No 16  
    RAD52 140004 Seq. ID No 10  
    C18B11 131988 Seq. ID No 12  
    MCM2 239799 Seq. ID No 11  
    MCF2L 1781388 Seq. ID No 8-9 
    TXNRD1 630625 Seq. ID No 17-21
  • To assess a breast cancer patient's relapse and metastatic potential, risk scores can be generated by using a Cox model of the 28-gene signature, independent of clinical-pathological parameters although any standard risk evaluation could be used. In this appication large value of the risk scores indicates a high risk of relapse/metastases, while a small value indicates a lower risk of breast cancer relapse. The 28-gene signature obtained from the training set (8) was fitted into a Cox regression model as covariates. To avoid overfitting, the data set are randomly partitioned into two subsets—one was used to define risk groups by fitting the model and obtaining the risk score cutoffs; the other subset was used to validate the cutoffs for defining the risk groups. The distribution of the risk scores can be categorized into groups of two or more. If two groups, patients could be labeled as high risk at the 65th percentile or above and low risk at 64th percentile and below. Alternatively, the patients could be categorized into high, low, or intermediate risk group is 39%, 26%, and 35%, respectively in the training set. The cutoffs defined in the training subset can be used to separate the patients in the test subset into high, low and intermediate risk groups.
  • A further embodiment is the ability to evaluate clincopathogic variables for cancer patients. Clincopathogic variable includes, but is not limited to, average metastases-free days, ER and PR status, age, tumor size, and tumor grade. Table 6 displays the clinical characteristics of each risk group, including average relapse-free days, ER status, Her2/neu overexpression, nodal status, age, tumor size, and treatment received on the data from Sotiriou et al.(8). Risk scores were generated for patients in Cox modeling using the gene expression profiles, without including clinicopathologic parameters. The 39th and 65th percentile of the risk scores were used to partition patients into high, intermediate, and low risk groups. Same analysis is applied to the two validation sets. Table 7 summarizes the clinical characteristics of each risk group, including average metastases-free days, ER and PR status, age, tumor size, and tumor grade on the data from van't Veer et al. (13). Table 8 summarizes the clinical characteristics of each risk group, including average relapse-free days, ER status, age, and tumor grade on the data from Sorlie et al.(10).
  • TABLE 6
    Clinical characteristics of each risk group on the
    patients from Sotiriou et al. (8)
    # of
    Her- % of % of
    Average % of 2\neu Tumor Positive % of
    Risk RFS Age ≧ positive Size > Nodal % of Hor- % of
    Group (days) 50 yrs cases 2 cm Status Chemo mone ER+
    High  969 82% 6 82% 67% 38% 79% 54%
    Inter. 2407 73% 1 58% 50% 35% 85% 58%
    Low 2781 65% 0 47% 41% 24% 74% 85%
  • TABLE 7
    Clinical characteristics of each risk group on the
    patients from van't Veer et al. (14)
    Average % of % of % of
    % of RFS Age ≧ % of Tumor T3/T4
    Risk Group Patients (days) 50 ER+ Grade 3 Tumors
    High 28% 553 50% 69% 81% 94%
    Intermediate 32% 801 84% 89% 26% 89%
    Low 40% 1376  70% 73% 32% 77%
  • TABLE 8
    Clinical characteristics of each risk group (Sorlie et al. (10))
    Average % of % of % of
    Risk % of RFS Age ≧ % of Tumor T3/T4
    Group Patients (days) 50 ER+ Grade 3 Tumors
    High 28% 553 50% 69% 81% 94%
    Intermediate 32% 801 84% 89% 26% 89%
    Low 40% 1376  70% 73% 32% 77%
  • Clinical variables such as nodal status, tumor size, tumor grade, ER status and HER2/neu overexpression in breast cancer patients affect the disease outcomes. The clinical characteristics of each risk group in the studied cohorts are analyzed including average disease-free survival days, ER and PR status, HER2/neu overexpression, nodal status, age, tumor size, grade, and treatment received. The 28-gene signature is strongly associated with the clincopathogic variables, including tumor size, tumor grade, ER and PR status, and HER2/neu overexpression (P<0.05; Table 9).
  • TABLE 9
    Association of gene expression-defined risk
    groups and clinicopathologic parameters
    P-Values
    Sotiriou van't Veer Sorlie et
    Risk Groups vs. et al.(8) et al.(15) al.(10)
    Age1 0.243  0.458  0.095 
    (<50 yrs or ≧50 yrs)
    Tumor size 0.006* 0.047*
    (<2 cm or >2 cm)
    Tumor grade 0.041* 0.004* 0.001*
    (1/2 vs. 3)
    ER status 0.011* 0.004* 0.296 
    PR status 0.001*
    Her2/neu 0.020*
    1The percentage of patients who were at least 50 years old was 74%, 28%, and 69% in the cohorts from Sotiriou et al. (8), van't Veer et al. (16), and Sorlie et al. (10), respectively.
  • The 28-gene signature also predicts tumor recurrence in ovarian cancer with an accuracy of 0.89 (FIG. 10). Table 10 listed the genes that are predictive of ovarian cancer relapse.
  • TABLE 10
    24 genes that quantifies relapse-free survival of breast cancer
    Gene Clone_IMAGE UniGene Cluster ID Sequence ID
    FAM134C 198917 Hs.463079 NM_178126  
    TOMM70A 198312 Hs.227253 NM_014820  
    MCF2 268412 Hs.387262 NM_001099855
    NM_005369  
    RAD52 Pseudogene 1377154 Hs.552577 NM_134424  
    MCM2 239799 Hs.477481 NM_004526  
    C18B11 131988 Hs.173311 NM_152260  
    SEC13L 757210 Hs.301048 NM_031216  
    NM_001013437
    SLC25A5 291660 Hs.522767 NM_001152  
    PLSCR1 268736 Hs.130759 NM_021105  
    TXNRD1 789376 Hs.434367 NM_003330  
    NM_001093771
    NM_182742  
    NM_182729  
    NM_182743  
    RAD50 261828 Hs.242635 NM_005732  
    NM_133482  
    INPPL1 703964 Hs.523875 NM_001567  
    PBX2 80549 Hs.509545 NM_002586  
    SSBP1 125183 Hs.490394 NM_003143  
    PDGFRA 376499 Hs.74615  NM_006206  
    DDOST 50666 Hs.523145 NM_005216  
    IGHA1 182930 Hs.497723 AK128652
    S100P 135221 Hs.2962  NM_005980  
    FAT 591266 Hs.481371 NM_005245  
    FGF2 324383 Hs.284244 NM_002006  
    INSM1 22895 Hs.89584  NM_002196  
    IRF5 260035 Hs.521181 NM_001098629
    NM_002200  
    NM_001098627
    NM_001098630
    NM_001098628
    NM_032643  
    NM_001098631
    MAP2K2 769579 Hs.465627 NM_030662  
  • In the present invention, target polynucleotide molecules are extracted from a sample taken from an individual afflicted with breast cancer or ovarian cancer. The sample may be collected in any clinically acceptable manner, but must be collected such that marker-derived polynucleotides (i.e., RNA) are preserved. mRNA or nucleic acids derived there from (i.e., cDNA or amplified DNA) can be labeled distinguishably from standard or control polynucleotide molecules, and both are simultaneously or independently hybridized to a detection mechanism. A detection mechanism can be any standard comparison mechanism such as a microarray or an assay of reverse transcription polymerase chain reaction (RT-PCR) comprising some or all of the markers or marker sets or subsets described above. This process identifies positive matches. Alternatively, mRNA or nucleic acids derived therefrom may be labeled with the same label as the standard or control polynucleotide molecules to identify positive matches, wherein the intensity of hybridization of each at a particular probe or primer is compared for such an identification. A sample may comprise any clinically relevant tissue sample, such as a tumor biopsy or fine needle aspiration, or a sample of bodily fluid, such as blood, plasma, serum, lymph, ascetic fluid, cystic fluid, urine, or nipple exudate. The sample may be taken from a human, or from non-human animals such as horses, mice, ruminants, swine or sheep. Patients' gene expression levels may be quantified by any means known in the art based on the marker sets defined above. Patients may be classified based on the quantitative expression profiles using any means known in the art. For example, the risk scores of a patient cohort may be generated using a Cox proportional hazard model. Patients with a risk score greater than the median is defined as high risk, whereas patients with a risk score less than the median is classified as low risk. Alternatively, a patient may be classified as high risk if this patient's gene expression profile is correlated with the high risk signature, or classified as low risk if this patient's gene expression profile is correlated with the low risk signature. A patient's prognostic categorization can also be determined by using a statistical model or a machine learning algorithm, which computes the probability of recurrence based on this patient's gene expression profiles. Cutoffs can be defined for patient stratification based on specific clinical setting. In addition, patients may be defined into three risk groups in the prognostic categorization based on the marker sets defined above.
  • Methods for preparing total and poly(A)+RNA are well known and are described in (17). RNA may be isolated from eukaryotic cells by procedures that involve cell lysis and denaturation of the proteins contained therein. Cells of interest include wide-type cells (i.e., no mutation), drug-treated wild-type cells, tumor- or tumor-derived cells, modified cells, normal or tumor cell lines cells, and drug-treated modified cells. Total RNA may also be extracted from samples using commercially available kits such as the RNeasy mini kit according the manufacturer's protocol (Qiagen, USA).
  • Additional steps may be performed to remove DNA (17). If desired, RNase inhibitors may be added to the lysis buffer. Likewise, a protein denaturation/digestion step may be added to the protocol. mRNA may be purified by means such as magnetic separation using Dynabeads (Dynal) or the Invitrogen FastTrack 2.0 kit (10).
  • For many applications, it is desirable to preferentially enrich mRNA with respect to other cellular RNAs, such as transfer RNA (tRNA) and ribosomal RNA (rRNA). Total RNA may also be linearly amplified using the original or modified Eberwine method (18) and be used as a reference for cDNA analysis (8).
  • The sample of RNA can comprise a plurality of different mRNA molecules, each different mRNA molecular having a different nucleotide sequence. In a specific embodiment, the RNA sample has not been functionally annotated.
  • The present invention provides a set of biomarkers for the identification of conditions of indications associated with breast cancer. Generally, the markers sets were identified by determining which of ˜25,000 human genes had expression patterns that correlated with the conditions or indications.
  • In one embodiment, the expression of all markers in a sample X is compared to the expression of all markers in the 28-gene signature or subsets as described above derived from tumor samples. The comparison may be accomplished by any means known in the art. The expression level may be determined by isolating and determining the level (i.e., the abundance) of nucleic acid transcribed from each marker gene. Alternatively, or additionally, the level of specific proteins translated from mRNA transcribed from a marker gene may be determined. For example, expression levels of various markers may be measured by separation of target nucleotide molecules (e.g., RNA or cDNA) derived from the markers in agarose or polyacrylamide gels, followed by hybridization with marker-specific oligonucleotide probes. Alternatively, the comparison may be accomplished by the labeling of target polynucleotide molecules followed by separation on a sequence gel. The comparison may also be accomplished by measuring the gene expression level using real-time reverse transcription polymerase chain reaction with marker-specific primers/probes. Patients may be classified based on the quantitative expression profiles using any means known in the art. For example, the risk scores of a patient cohort may be generated using a Cox proportional hazard model. Patients with a risk score greater than the median is defined as high risk, whereas patients with a risk score less than the median is classified as low risk. Alternatively, a patient may be classified as high risk if this patient's gene expression profile is correlated with the high risk signature, or classified as low risk if this patient's gene expression profile is correlated with the low risk signature. A patient's prognostic categorization can also be determined by using a statistical model or a machine learning algorithm, which computes the probability of recurrence based on this patient's gene expression profiles. Cutoffs can be defined for patient stratification based on specific clinical setting. In addition, patients may be defined into three risk groups in the prognostic categorization based on the marker sets defined above.
  • A marker is selected based on its predictive power of breast cancer recurrence, including local recurrence and distant metastasis. A combination of Random Forests (19) and Linear Discriminant Analysis (LDA) is used to identify gene signatures for predicting breast cancer recurrence/metastases. Random forests of software R is first used to identify a small subset of genes from the original microarray data. Linear Discriminant Analysis of software SAS is used to further refine the gene signature.
  • Random forests are a generalization of the standard tree algorithms (20). The basic step of random forests is to form diverse tree classifiers from a single training set. Each tree is built upon a bootstrap sample from the training set. The variables used for splitting the tree nodes are a random subset of the whole variables set. The classification decision of a new case is obtained by majority voting (unless the cutoff value is user defined) over all trees. In random forests, about one-third of the cases in the bootstrap sample are not used in growing the tree. These cases are called “out-of-bag” (OOB) cases and are used to evaluate the algorithm performance. A very important function of random forests is variable importance evaluation. The importance of a variable is defined in terms of its contribution to classification accuracy. Based on the variable importance measure, backward elimination was used to identify the gene subset with the smallest OOB error rate. Here, the OOB error rate was not used to assess the prediction accuracy of the identified gene subsets. Instead, it served as a stopping rule for feature selection. The varSelRF package of software R (21) was used according to the following steps:
      • 1. Build a forest with N trees and obtain a ranking of variable importance
      • 2. Remove 20% of the least important variables
      • 3. Construct a new forest with K trees
      • 4. Repeat steps 2 and 3 until two genes are left
      • 5. Select the gene subset with the smallest OOB error rate
  • In the experiments, N=3,000 and K=1,000 are chosen because the large number of trees in the initial forests are likely to produce stable importance measures (21). The “0-Standard Error (0-SE) rule” is used, which identifies the gene subset with the smallest OOB error rate. The “0-SE rule” usually selects more genes than the “1-SE rule” does. Since further gene filtering would be performed by using Linear Discriminant Analysis, the gene subsets are selected with the lowest prediction error using random forests.
  • Discriminant analysis is used to determine which variables discriminate two or more naturally occurring groups in prognosis. Given a number of variables as the data representation, each class is modeled as multivariate normal distribution with a covariance matrix and a mean vector. Instances are classified to the label of the nearest mean vector based on Mahalanobis distance. The decision surfaces between classes become linear if the classes have a common covariance matrix. When the distribution within each group is assumed to be multivariate normal, a parametric method can be used to develop a discriminant function. Such function is determined by a measure of generalized square distance which is based on the pooled covariance matrix as well as the prior probabilities of group membership. The generalized squared distance Di 2(x) from input x to class i is:

  • D i 2(x)=d i 2(x)+g(i)
  • where di 2(x)=(x−mi)′V−1(x−mi) is the squared distance from x to group I; m, is the p-dimensional mean vector for group I; V is the pooled covariance matrix and g(i) depends on the prior probability of class i. In practice, the prior probability can be assumed as equal for all groups (refer to SAS Users' Manual). In this study, we assumed equal prior probability and thus g(i)=0. x is classified into class I, if Di 2(x) is the smallest among all the distance measures. We selected the gene markers using backward selection of stepwise discriminant analysis with software SAS.
  • Linear Discriminant Analysis (LDA) is used to refine the gene signature obtained from random forests and assess the classification accuracy of models in predicting 5-year relapse-free survival based on the identified gene signatures. Leave-one-out cross-validation is used in the evaluation to identify the optimal marker subset (22).
  • Once a marker set is identified, validation of the marker set may be accomplished by a survival analysis. To evaluate the accuracy of survival prediction, time-dependent receiver operating characteristic (ROC) analysis for censored data (23; 24) was performed with software R. Time-dependent ROC analysis extends the concepts of sensitivity, specificity, and ROC curves for time-dependent binary disease variables in censored data. In this embodiment, the binary disease variable R,(t)=1, if patient i has recurrent or metastatic breast cancer prior to time t; otherwise, R,(t)=0. For a diagnostic marker M, both sensitivity and specificity are defined as a function of time t:

  • sensitivity(c,t)=P{M>c|R(t)=1}

  • specificity(c,t)=P{M≦c|R(t)=0 }
  • A ROC(t) is a function of t at different cutoffs c. A time-dependent ROC curve is a plot of sensitivity(c, t) vs. 1−specificity(c, t). The area under the ROC curve (AUC) can be used as an accuracy measure of the ROC curve. A higher prediction accuracy is evidenced by a larger AUC(t) (23; 24).
  • The prediction of patient outcome may be accomplished with any means known in the art. For example, to estimate a patient's recurrent and metastatic potential, risk scores are generated by fitting the identified gene predictors in a Cox proportional hazard model as covariates. A higher risk score represents a higher probability of tumor recurrence. The distribution of the risk scores can be used to classify the patients into three groups: high-risk, low-risk, and intermediate-risk. Alternatively, patients may be stratified into two groups: high- or low-risk. Kaplan-Meier analysis may be used to assess the disease-free survival probability of three risk groups in the studied patient cohorts (8; 10; 25). Similarly, a Cox proportional hazard model may be developed to estimate a patient's overall survival probability. A higher survival risk score represents a higher risk for death from breast cancer. Alternatively, a Linear Discriminant Analysis (LDA) function may be determined by a measure of generalized square distance which is based on the pooled covariance matrix based on the marker sets described above as well as the prior probabilities of group membership for prognostic categorization.
  • For prognostic predictions in clinic, the expression levels of the markers can be measured with any means known in the art such as cDNA microarrays (8; 10; 26), various generations of Affymetrix gene chips (Affymetrix, Santa Clara, Calif.), and real-time reverse transcription polymerase chain reactions. The present invention further provides for kits comprising the marker sets above. The analytical methods described above can be implemented by use of following computer systems. For example, a computer system can be an Intel 8086-, 80386-, 80486-, or Pentium-based process with preferably 64 MB or more of main memory. The computer system can be linked to an external component, including mass storage. This mass storage can be one or more hard disks, preferably of 1 GB or more storage capacity. Other external components include regular accessories for a computer such as a monitor, a mouse, or a printer.
  • The software program described in above sections can be implemented with software packages R and SAS. The software to be included in the kit comprises the data analysis methods for this invention as disclosed herein. In particular, the software algorithms may include mathematical procedures for biomarker discovery, including the computation of the Mahalanobis distance between clinical categories (i.e., relapse status) and marker expression. The software may also include mathematical procedures for computing the regression coefficients between the marker expression and patient survival.
  • Alternative computer systems and software for implementing the analytical methods of this invention will be apparent to one of skill in the art and are intended to be comprehended within the accompanying claims.
  • These terms and specifications, including the examples, serve to describe the invention by example and not to limit the invention. It is expected that others will perceive differences, which, while differing from the forgoing, do not depart from the scope of the invention herein described and claimed. In particular, any of the function elements described herein may be replaced by any other known element having an equivalent function.
    • REFERENCE LIST
    • 1. Gonzalez M A, Pinder S E, Callagy G, Vowler S L, Morris L S, Bird K, Bell J A, Laskey R A, Coleman N. Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J. Clin. Oncol. 2003 Dec. 1;21(23):4306-13.
    • 2. Tommiska J, Seal S, Renwick A, Barfoot R, Baskcomb L, Jayatilake H, Bartkova J, Tallila J, Kaare M, Tamminen A, et al. Evaluation of RAD50 in familial breast cancer predisposition. Int. J. Cancer 2006 Jun. 1;118(11):2911-6.
    • 3. Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res. 2005;7(5):R788-R795.
    • 4. Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C, Beug H, Grunert S. Autocrine PDGFR signaling promotes mammary cancer metastasis. J. Clin. Invest 2006 June; 116(6): 1561-70.
    • 5. Guerreiro D S, I, Hu Y F, Russo I H, Ao X, Salicioni A M, Yang X, Russo J. S100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo. Int. J. Oncol. 2000 February;16(2):231-40.
    • 6. Schor A P, Carvalho F M, Kemp C, Silva I D, Russo J. S100P calcium-binding protein expression is associated with high-risk proliferative lesions of the breast. Oncol. Rep. 2006 January;15(1):3-6.
    • 7. Granato A M, Nanni O, Falcini F, Folli S, Mosconi G, De Paola F, Medri L, Amadori D, Volpi A. Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools? Breast Cancer Res. 2004;6(1):R38-R45.
    • 8. Sotiriou C, Neo S Y, McShane L M, Korn E L, Long P M, Jazaeri A, Martiat P, Fox S B, Harris A L, Liu E T. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. U.S.A 2003 Sep. 2;100(18):10393-8.
    • 9. 't Veer L J, Dai H, van de Vijver M J, He Y D, Hart A A, Mao M, Peterse H L, van der K K, Marton M J, Witteveen A T, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 Jan. 31;415(6871):530-6.
    • 10. Sorlie T, Perou C M, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen M B, van de R M, Jeffrey S S, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A 2001 Sep. 11;98(19):10869-74.
    • 11. 't Veer L J, Dai H, van de Vijver M J, He Y D, Hart A A, Mao M, Peterse H L, van der K K, Marton M J, Witteveen A T, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 Jan. 31;415(6871):530-6.
    • 12. 't Veer L J, Dai H, van de Vijver M J, He Y D, Hart A A, Mao M, Peterse H L, van der K K, Marton M J, Witteveen A T, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 Jan. 31;415(6871):530-6.
    • 13. 't Veer L J, Dai H, van de Vijver M J, He Y D, Hart A A, Mao M, Peterse H L, van der K K, Marton M J, Witteveen A T, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 Jan. 31;415(6871):530-6.
    • 14. 't Veer L J, Dai H, van de Vijver M J, He Y D, Hart A A, Mao M, Peterse H L, van der K K, Marton M J, Witteveen A T, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 Jan. 31;415(6871):530-6.
    • 15. 't Veer L J, Dai H, van de Vijver M J, He Y D, Hart A A, Mao M, Peterse H L, van der K K, Marton M J, Witteveen A T, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 Jan. 31;415(6871):530-6.
    • 16. 't Veer L J, Dai H, van de Vijver M J, He Y D, Hart A A, Mao M, Peterse H L, van der K K, Marton M J, Witteveen A T, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 Jan. 31;415(6871):530-6.
    • 17. Sambrook J, Russell D W. Molecular Cloning: A Laboratory Manual. 3rd ed. Cold Spring Harbor Laboratory Press; 2001.
    • 18. Eberwine J, Yeh H, Miyashiro K, Cao Y, Nair S, Finnell R, Zettel M, Coleman P. Analysis of Gene Expression in Single Live Neurons. PNAS 1992 Apr. 1;89(7):3010-4.
    • 19. Breiman L. Random Forests. Machine Learning 2001;45:5-32.
    • 20. Bioinformatics and Computational Biology Solutions. 1st ed. New York: Springer; 2005.
    • 21. Diaz-Uriarte R, Alvarez dA. Gene selection and classification of microarray data using random forest. BMC. Bioinformatics. 2006;7:3.
    • 22. Kohavi R. A Study of Cross-Validation and Bootstrap for Accuracy Estimation and Model Selection. Proceedings.of International Joint Conference on Artificial Intelligence (IJCAI) 1995;1137-43.
    • 23. Heagerty P J, Lumley T, Pepe M S. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000 June;56(2):337-44.
    • 24. Heagerty P J, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics 2005;61:92-105.
    • 25. 't Veer L J, Dai H, van de Vijver M J, He Y D, Hart A A, Mao M, Peterse H L, van der K K, Marton M J, Witteveen A T, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 Jan. 31;415(6871):530-6.
    • 26. van 't Veer L J, Dai H, van de Vijver M J, He Y D, Hart A A, Mao M, Peterse H L, van der K K, Marton M J, Witteveen A T, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 Jan. 31;415(6871):530-6.
    • 27. 't Veer L J, Dai H, van de Vijver M J, He Y D, Hart A A, Mao M, Peterse H L, van der K K, Marton M J, Witteveen A T, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 Jan. 31;415(6871):530-6.
    • 28. 't Veer L J, Dai H, van de Vijver M J, He Y D, Hart A A, Mao M, Peterse H L, van der K K, Marton M J, Witteveen A T, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 Jan. 31;415(6871):530-6.
    • 29. Bild A H, Yao G, Chang J T, Wang Q, Potti A, Chasse D, Joshi M B, Harpole D, Lancaster J M, Berchuck A, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006 Jan. 19;439(7074):353-7.

Claims (2)

1. A gene signature comprising nucleic acids wherein the nucleic acids consist of Seq. ID No. 8-12, 16-24, 26, 27, 29, 31, 32, 42-44 wherein the nucleic acids are a breast cancer relapse and metastatic potential prognosticator.
2. The gene signature of claim 1 wherein the nucleic acids further consist of Seq. ID No. 3, 7, 13-15, 25, 30, 33, 34-41.
US13/340,003 2007-03-22 2011-12-29 Gene Signature for Diagnosis and Prognosis of Breast Cancer and Ovarian Cancer Abandoned US20120123105A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/340,003 US20120123105A1 (en) 2007-03-22 2011-12-29 Gene Signature for Diagnosis and Prognosis of Breast Cancer and Ovarian Cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91936907P 2007-03-22 2007-03-22
US12/077,992 US8030060B2 (en) 2007-03-22 2008-03-24 Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer
US12/661,286 US20110224908A1 (en) 2007-03-22 2010-03-15 Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer
US13/340,003 US20120123105A1 (en) 2007-03-22 2011-12-29 Gene Signature for Diagnosis and Prognosis of Breast Cancer and Ovarian Cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/661,286 Continuation US20110224908A1 (en) 2007-03-22 2010-03-15 Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer

Publications (1)

Publication Number Publication Date
US20120123105A1 true US20120123105A1 (en) 2012-05-17

Family

ID=40932060

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/077,992 Active - Reinstated 2029-04-20 US8030060B2 (en) 2007-03-22 2008-03-24 Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer
US12/661,286 Abandoned US20110224908A1 (en) 2007-03-22 2010-03-15 Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer
US13/340,003 Abandoned US20120123105A1 (en) 2007-03-22 2011-12-29 Gene Signature for Diagnosis and Prognosis of Breast Cancer and Ovarian Cancer

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US12/077,992 Active - Reinstated 2029-04-20 US8030060B2 (en) 2007-03-22 2008-03-24 Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer
US12/661,286 Abandoned US20110224908A1 (en) 2007-03-22 2010-03-15 Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer

Country Status (1)

Country Link
US (3) US8030060B2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140235487A1 (en) * 2010-11-12 2014-08-21 William Marsh Rice University Oral cancer risk scoring
GB201121924D0 (en) * 2011-12-20 2012-02-01 Fahy Gurteen Labs Ltd Detection of breast cancer
AU2013243300B2 (en) * 2012-04-05 2018-12-06 Oregon Health & Science University Gene expression panel for breast cancer prognosis
US20150267259A1 (en) * 2012-10-12 2015-09-24 Agency For Science, Technology And Research Method of prognosis and stratification of ovarian cancer
KR102359214B1 (en) 2014-04-04 2022-02-07 델 마 파마슈티컬스 Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
CN106324247B (en) * 2015-06-26 2018-06-26 复旦大学附属肿瘤医院 The application of SSBP1 albumen
CN106326688B (en) * 2016-08-26 2017-10-24 章乐 A kind of higher-dimension lacks the choosing method of the gene, signal path and related protein of sample
CN107832583B (en) * 2017-11-08 2021-04-16 武汉大学 A cross-species biological pathway discovery method based on graph matching
WO2020023676A1 (en) * 2018-07-25 2020-01-30 The University Of Chicago Use of metastases-specific signatures for treatment of cancer
CN112037863B (en) * 2020-08-26 2022-06-21 南京医科大学 Early NSCLC prognosis prediction system
CN113096739B (en) * 2021-04-09 2024-04-12 东南大学 An analysis method for a combination of immune prognostic diagnostic markers for ovarian cancer
CN117153392B (en) * 2023-08-25 2024-08-27 几象智造(深圳)科技有限公司 Marker for prognosis prediction of gastric cancer, assessment model and construction method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
DK1410011T3 (en) * 2001-06-18 2011-07-18 Netherlands Cancer Inst Diagnosis and prognosis of breast cancer patients
WO2005039382A2 (en) * 2003-06-24 2005-05-06 Genomic Health Prediction of likelihood of cancer recurrence

Also Published As

Publication number Publication date
US8030060B2 (en) 2011-10-04
US20110224908A1 (en) 2011-09-15
US20090197259A1 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
US20120123105A1 (en) Gene Signature for Diagnosis and Prognosis of Breast Cancer and Ovarian Cancer
Yu et al. Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer
KR101530689B1 (en) Prognosis prediction for colorectal cancer
JP7228896B2 (en) Methods for predicting the prognosis of breast cancer patients
JP6404304B2 (en) Prognosis prediction of melanoma cancer
CN112292697A (en) Machine learning embodiments for multi-analyte determination of biological samples
US20090062144A1 (en) Gene signature for prognosis and diagnosis of lung cancer
CA2608643A1 (en) Gene-based algorithmic cancer prognosis
Chen et al. Integrating biological knowledge with gene expression profiles for survival prediction of cancer
CN110423816B (en) Breast cancer prognosis quantitative evaluation system and application
AU2008203226B2 (en) Colorectal cancer prognostics
JP2022141708A (en) A method to predict the efficacy of chemotherapy in breast cancer patients
EP2419540B1 (en) Methods and gene expression signature for assessing ras pathway activity
Lenoci et al. Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities
WO2014066984A1 (en) Method for identifying a target molecular profile associated with a target cell population
WO2015154715A1 (en) A method of diagnosis, prognosis or treatment of a cancer
WO2021213981A1 (en) Multi-gene expression assay for prostate carcinoma
EP1512758B1 (en) Colorectal cancer prognostics
US10240206B2 (en) Biomarkers and methods for predicting benefit of adjuvant chemotherapy
Ring et al. Predicting the sites of metastases
JP5963748B2 (en) Prognosis prediction method, kit and use of patients with primary malignant lymphoma of central nervous system
JP2011211989A (en) Method for prognostic prediction of malignant glioma patient
JP2015000006A (en) Method and kit for predicting prognosis of patients with malignant glioma Grade 4
Fan et al. CM Perou.* These authors contributed equally to this work. This work is in press in the New England Journal of Medicine. 2006.
Zhao et al. Breast Cancer Prognostication and Risk Prediction in the Post-Genomic Era

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION